Navigation Links
The Effectiveness Of The Breast Cancer Drug By Pfizer

Pfizer has increased the survival rate of breast cancer patients by 63 percent with their latest drug compared to the standard regimes available . The clinical trial strengthens the case for administering the newer drug, exemestane, as a first option.// A study showed that women recovering from breast cancer lowered their chance of developing another tumor by 32 percent if they switched to exemestane after two or three years of tamoxifen treatment.

According to the research presented this week at a breast cancer conference , the median survival for patients taking exemestane was 10.9 months, compared with 6.7 months for patients on tamoxifen. About 44.2 percent of patients in the study had tumors that responded either partially or fully to exemestane , compared with 29.2 percent on tamoxifen. The difference was statistically significant. These reports have been substantiated by specialists in the field who began trying the drug in patients in 1989, well before it was approved.

Tamoxifen is sold under the brand name Nolvadex by AstraZeneca Plc and is usually taken for five years. Tamoxifen works by blocking the hormone estrogen, which can stimulate and feed the growth of breast cancer.

By contrast, exemestane was the first approved oral therapy that binds to an enzyme known as aromatase, which normally converts the hormone androgen into estrogen in postmenopausal women. The drug thereby curtails the actual supply of estrogen to the cancerous tumors that are dependent on it, rather than blocking estrogen after it is already produced. Pfizer markets exemestane under the brand name Aromasin.

Researchers say ,"These (studies) are pieces of the puzzle, and the puzzle is becoming clearer now."
'"/>




Page: 1

Related medicine news :

1. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
2. The Effectiveness Of Screening Tests Questioned
3. The Effectiveness Of Chickenpox Vaccine Questioned
4. The Effectiveness Of Antibacterial Products In Reducing Infection
5. The Effectiveness Of Cancer Drug In Women At Risk Of Developing Cancer
6. Effectiveness Of Prostate Cancer Test
7. Studying The Effectiveness Of Cough Syrups
8. The Effectiveness Of NSAIDs Evaluated
9. Effectiveness Of Infertility Treatments Questioned
10. Report on the Safety and Effectiveness of Melatonin supplements
11. The Effectiveness Of Inhaled Corticosteroids Studied
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... ... March 24, 2017 , ... The iaedp Foundation, the premier ... professionals caring for those suffering from the full spectrum of disordered eating, announced today ... disorders professionals from nearly all 50 states and several countries converged on the Green ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the ... product – with nearly 2,000 consumers (and counting) already backing the campaign. ...
(Date:3/24/2017)... Oakland, CA (PRWEB) , ... March 24, 2017 ... ... present on two panels at the Advanced ERISA Benefit Claims Litigation seminar in ... and Creating the Administrative Record, The majority of cases litigated under ERISA involve ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health (“GH”) ... prep patients for colonoscopy at the HyGIeaCare® Center that is to be located ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... to Walk with God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward ... Learning How to Walk with God #TruthwithGrace” is the creation of published author ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... 2016" report to their offering. ... The IPF pipeline is very strong with a total of ... Co., Inc., Biogen and Sanofi are involved in the development of the ... one is in Phase III stage, 15 are in Phase II stage, ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... their offering. ... provides separate comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America , and Rest of ... 2022. Also, a six-year historic analysis is provided for these markets. Market ...
(Date:3/24/2017)... March 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... Commitment Term Sheet (the "Definitive Financing") it entered ... the Company,s stockholders, who are referred to in ... Form 8-K filed with the Securities and Exchange ...
Breaking Medicine Technology: